MegaPro Biomedical Co (ROCO:6827) Cash-to-Debt : 3.89 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is MegaPro Biomedical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MegaPro Biomedical Co's cash to debt ratio for the quarter that ended in Jun. 2023 was 3.89.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MegaPro Biomedical Co could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for MegaPro Biomedical Co's Cash-to-Debt or its related term are showing as below:

ROCO:6827' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.46 Med: 5007.65 Max: No Debt
Current: 15.3

During the past 6 years, MegaPro Biomedical Co's highest Cash to Debt Ratio was No Debt. The lowest was 12.46. And the median was 5007.65.

ROCO:6827's Cash-to-Debt is ranked better than
61.54% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs ROCO:6827: 15.30

MegaPro Biomedical Co Cash-to-Debt Historical Data

The historical data trend for MegaPro Biomedical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MegaPro Biomedical Co Cash-to-Debt Chart

MegaPro Biomedical Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

12.46

13.20

15.30

MegaPro Biomedical Co Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial					12.46	13.00	13.20	3.89	15.30

Competitive Comparison of MegaPro Biomedical Co's Cash-to-Debt

For the Biotechnology subindustry, MegaPro Biomedical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MegaPro Biomedical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MegaPro Biomedical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MegaPro Biomedical Co's Cash-to-Debt falls into.

MegaPro Biomedical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MegaPro Biomedical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	127.256	/	(2.69	+	5.628)
	=	15.30

MegaPro Biomedical Co's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	37.495	/	(2.65	+	6.983)
	=	3.89

MegaPro Biomedical Co (ROCO:6827) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

MegaPro Biomedical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MegaPro Biomedical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MegaPro Biomedical Co (ROCO:6827) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MegaPro Biomedical Co Ltd (ROCO:6827) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Section 4, Chung Hsing Road, Suite 526, Building 52, No.195, Chutung, Hsinchu, TWN, 31040

Website

https://www.megaprobio.com

MegaPro Biomedical Co Ltd is a nanomedicine development company.

MegaPro Biomedical Co (ROCO:6827) Headlines

No Headlines